Aesica forms alliance with Noramco
For the manufacture of codeine
Aesica has developed an innovative manufacturing relationship with Noramco to provide the UK market with an alternative source of controlled drugs.
The two firms have formed an integrated value chain comprising raw material supply security, technical excellence, production facilities and regulatory expertise.
The alliance has involved technical transfer of a process for the manufacture of codeine phosphate from a unique, patented poppy supplied by Noramco’s sister company, Tasmanian Alkaloids, allowing for the conversion of the extracted alkaloid to a finished active pharmaceutical ingredient (API) in a one-step process. This in turn has led to a reduction in the environmental impact of the production of the API and lends itself to a superior environmentally produced and competitive product.
Aesica has utilised its technical advantages of a fully computer-controlled facility that has the ability to provide higher process control compared with other manufacturing facilities. The API production facility has considerable advantages over a manual plant, in that Aesica can demonstrate the robust nature of the process, as well as a reduction in the costs of production. By using this lean methodology Aesica aspires to set a benchmark for the European pharmaceutical industry.
Dr Robert Hardy, ceo of Aesica, said: ‘Although we already have experience in manufacturing controlled drugs, our aim was always to create a manufacturing alliance with another experienced API developer to enable us to establish a leading presence. Our manufacturing expertise coupled with our established infrastructure, understanding and capability in terms of regulatory compliance and security were particularly attractive to Noramco.
‘Moreover, our heritage and brand values reflected those of Noramco and there is a natural cultural fit, as we are both committed to constantly improving and enhancing our offering.
‘Most important though, we are determined that the new manufacturing process we have developed with Noramco will re-invigorate the controlled drug market in the UK creating added value for customers and drive future innovations.’
Noramco, a global manufacturer and supplier of opiate-derived APIs, will sell codeine manufactured by Aesica through its Europe-based sales team.
‘We are excited to supply the UK and other world markets from Aesica and have had very good response thus far from customers seeking a secure, integrated source of codeine and controlled ingredients,’ stated Leslie Storms, vice president, Global Sales at Noramco.
‘Partnering a company with Aesica’s reputation for quality and performance has given our customers even greater confidence in our supply chain.’
Aesica is a full-service provider of contract research, development and manufacturing services for Formulated Products and Active Pharmaceutical Ingredients.